PubRank

Khusru Asadullah

Author PubWeight™ 104.98‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 2011 22.33
2 A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012 14.63
3 IL-22 increases the innate immunity of tissues. Immunity 2004 8.30
4 Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002 5.43
5 IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006 4.88
6 Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002 3.63
7 IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol 2007 1.80
8 Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 2003 1.71
9 The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-alpha pathway of systemic and cutaneous inflammation. J Invest Dermatol 2009 1.53
10 Crowd sourcing in drug discovery. Nat Rev Drug Discov 2011 1.51
11 Immunopathogenesis of psoriasis. Exp Dermatol 2007 1.44
12 Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006 1.41
13 Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006 1.40
14 Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007 1.39
15 Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 2007 1.32
16 Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 2005 1.31
17 Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008 1.26
18 The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009 1.19
19 Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol 2004 1.14
20 Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy 2004 1.12
21 Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol 2009 1.02
22 Heme oxygenase-1 inhibits T cell-dependent skin inflammation and differentiation and function of antigen-presenting cells. Exp Dermatol 2007 1.02
23 An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol 2002 1.01
24 Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur J Immunol 2004 0.98
25 Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index. Curr Opin Investig Drugs 2005 0.96
26 A novel immunosuppressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity. J Invest Dermatol 2002 0.94
27 Immunomodulation by a novel, dissociated Vitamin D analogue. Exp Dermatol 2009 0.92
28 Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index. Exp Dermatol 2006 0.92
29 What makes a good drug target? Drug Discov Today 2011 0.92
30 Role of fucosyltransferases in leukocyte trafficking: major impact for cutaneous immunity. Trends Immunol 2003 0.90
31 IL-10 protects monocytes and macrophages from complement-mediated lysis. J Leukoc Biol 2009 0.90
32 Cytokine and anticytokine therapy in dermatology. Expert Opin Biol Ther 2003 0.87
33 CCR4 and CCR10 ligands play additive roles in mouse contact hypersensitivity. Exp Dermatol 2008 0.86
34 Fumaric acid esters are potent immunosuppressants: inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate. Arch Dermatol Res 2002 0.86
35 Techniques: species' finest blend--humanized mouse models in inflammatory skin disease research. Trends Pharmacol Sci 2004 0.86
36 Targeting leukocyte trafficking to inflamed skin: still an attractive therapeutic approach? Exp Dermatol 2007 0.85
37 Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs 2006 0.85
38 Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. Dermatoendocrinol 2011 0.84
39 Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases. Exp Dermatol 2011 0.82
40 Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. J Invest Dermatol 2002 0.82
41 [Founding the new German Skin Research Center]. J Dtsch Dermatol Ges 2007 0.81
42 Selectin and selectin ligand binding: a bittersweet attraction. J Clin Invest 2003 0.80
43 Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis. J Leukoc Biol 2008 0.80
44 Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs. Drug Discov Today 2010 0.80
45 Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. Exp Dermatol 2007 0.80
46 Persistent CMV infection correlates with disease activity and dominates the phenotype of peripheral CD8+ T cells in psoriasis. Exp Dermatol 2011 0.80
47 The glucocorticoid receptor as target for classic and novel anti-inflammatory therapy. Curr Drug Targets Inflamm Allergy 2004 0.80
48 Keratinocyte unresponsiveness towards interleukin-10: lack of specific binding due to deficient IL-10 receptor 1 expression. Exp Dermatol 2003 0.79
49 What makes a good drug target? Drug Discov Today 2011 0.78
50 RNA interference-mediated gene silencing in murine T cells: in vitro and in vivo validation of proinflammatory target genes. Cell Commun Signal 2008 0.78
51 Animal models of T-cell-mediated skin diseases. Bioessays 2004 0.77
52 Ultraviolet B radiation-mediated inhibition of interferon-gamma-induced keratinocyte activation is independent of interleukin-10 and other soluble mediators but associated with enhanced intracellular suppressors of cytokine-signaling expression. J Invest Dermatol 2003 0.77
53 Efomycine M: an inhibitor of selectins? Nat Med 2006 0.75
54 Cytokines as potential therapeutic targets for inflammatory skin diseases. Eur Cytokine Netw 2005 0.75
55 Willingness to Donate Human Samples for Establishing a Dermatology Research Biobank: Results of a Survey. Biopreserv Biobank 2011 0.75
56 The immunological synapse: kinases in T cell signalling as potential drug targets. Immunol Lett 2006 0.75
57 Shortened treatment duration of glucocorticoid-induced skin atrophy in rats. Exp Dermatol 2011 0.75
58 Biomarkers for intensive care medicine patients: the (stony) path into a bright future? Biomarkers 2011 0.75
59 Nuclear receptors: old targets, new opportunities. Curr Drug Targets Inflamm Allergy 2004 0.75
60 Humanised mouse models in drug discovery for skin inflammation. Expert Opin Drug Discov 2006 0.75
61 [New developments in the systemic treatment of psoriasis]. J Dtsch Dermatol Ges 2003 0.75